While gene-specific replacement therapies have achieved landmark success with voretigene neparvovec (Luxturna) for biallelic <i>RPE65</i>-associated retinal dystrophy, developing individual therapies for each genetic subtype remains impractical. Here, RPE65 is linked to inherited retinal dystrophy.